Andor Glaudemans
prof. dr.
I am a nuclear medicine specialist and always trying to implement innovative diagnostic and therapeutic methods in imaging. My main research interests involve infectious and inflammatory diseases, tumor-immunology, and development of new-targeted diagnostic tools for PET imaging. The latter focus is carried out in close collaboration with our radiochemists. Within the lymphoma research Groningen team we have a close collaboration with the department of hematology. The research is focused on finding new methods for diagnosis and therapy evaluation in several types of lymphomas. We have a special interest in post-transplant lymphatic disorders (PTLD). Furthermore, we are developing and evaluating several fields of radionuclide therapy, so called theranostics.
Molecular imaging in ovarian cancer
Published in: Annals of Oncology
Access to document
10.1093/annonc/mdw091
Ovarian cancer has a high mortality and novel-targeted treatment strategies have not resulted in breakthroughs for this disease. Insight into the molecular characteristics of ovarian tumors may improve diagnosis and selection of patients for treatment with targeted therapies. A potential way to achieve this is by means of molecular imaging. Generic tumor processes, such as glucose metabolism (F-18-fluorodeoxyglucose) and DNA synthesis (F-18-fluorodeoxythymidine), can be visualized non-invasively. More specific targets, such as hormone receptors, growth factor receptors, growth factors and targets of immunotherapy, can also be visualized. Molecular imaging...
A K L Reyners, K E Broekman, A W J M Glaudemans, A H Brouwers, H J G Arts, A G J van der Zee, E G E de Vries, M Jalving
PET/CT imaging of Mycobacterium tuberculosis infection.
Published in: Clinical and Translational Imaging
Access to document
10.1007/s40336-016-0164-0
document
Tuberculosis has a high morbidity and mortality worldwide. Mycobacterium tuberculosis (Mtb) has a complex pathophysiology; it is an aerobic bacillus capable of surviving in anaerobic conditions in a latent state for a very long time before reactivation to active disease. In the latent tuberculosis infection, the individual has no clinical evidence of active disease, but exhibits a hypersensitive response to proteins of Mtb. Only some 5-10 % of latently infected individuals appear to have reactivation of tuberculosis at any one time point after infection, and neither imaging nor...
Alfred Ankrah, Tjip Werf, van der, Erik de Vries, Rudi Dierckx, M. M. Sathekge, Andor W.J.M. Glaudemans
Vessel involvement in giant cell arteritis: an imaging approach
Vasculitis is classified based on the size of the involved vessels. The two major forms are small vessel vasculitis and large vessel vasculitis (LVV). Main forms of LVV are Takayasu arteritis, giant cell arteritis (GCA), isolated aortitis and chronic periaortitis. This manuscript will focus on GCA, named after the presence of giant cells in the artery vessel wall. A positive biopsy of the temporal artery is the gold standard for making a diagnosis of GCA. In the past 10 years the introduction of new imaging techniques in GCA...
Pieter W. Holm, Maria Sandovici, Riemer H. J. A. Slart, Andor W. J. M. Glaudemans, Abraham Rutgers, Elisabeth Brouwer
A phase 1 dose escalation study of RAD1901, an oral selective estrogen receptor degrader, in healthy postmenopausal women
Published in: Cancer Research
Access to document
10.1158/1538-7445.SABCS15-P6-13-02
Estrogen and the estrogen receptor (ER) are known to be prominent drivers of breast tumourigenesis and breast cancer progression. Hormonal agents that target the ER such as selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) are routinely used for the management for ER+ breast cancer. Fulvestrant is currently the only SERD approved for the treatment of ER-positive metastatic breast cancer, however, despite its clinical efficacy, the utility of fulvestrant has been limited by the amount of drug that can be administered in a single injection,...
G. Hattersley, F. David, A. Harris, M. Clarkin, K. Banks, A. W. J. M. Glaudemans, J. Doorduin, M. Koole, E. F. J. de Vries, G. Williams
Radiotherapy may induce enhanced uptake on F-18-fluoroestradiol PET scans
Published in: Cancer Research
Access to document
10.1158/1538-7445.SABCS15-P5-01-07
Introduction: Whole body imaging of 18F-fluoroestradiol (FES) uptake combined with positron emission tomography (PET) has been applied for diagnosis and prediction of therapy response in estrogen receptor (ER) positive breast cancer patients. A maximal standardized uptake value (SUVmax) of 1.5 has previously been defined as the optimal threshold for FES uptake to differentiate between ER-positive and negative tumor lesions. FES uptake in healthy tissue differs per anatomic site and can be influenced by extrinsic factors. Previous FES PET studies have suggested that radiotherapy (RTx) may cause heterogeneous enhanced...